Key result
High-throughput metabolomics techniques show potential in identifying metabolic biomarkers for the pathogenesis, early diagnosis, and prognosis of common valvular heart diseases.
Why the study?
Gaps remain in the understanding of the pathogenesis of common valvular heart diseases, prompting a review of the contribution of metabolomics to their development, diagnosis, and prognosis.
What is the role of high-throughput metabolomics in understanding the pathogenesis, diagnosis, and prognosis of valvular heart disease?
What is the role of high-throughput metabolomics in understanding the pathogenesis, diagnosis, and prognosis of valvular heart disease?
High-throughput metabolomics may offer reliable metabolic biomarkers to supplement existing diagnostic tools for early diagnosis and prognosis of valvular heart disease.
Metabolomic biomarkers should not yet guide valvular heart disease care; leaves open need for prospective validation.
High-throughput metabolomics techniques are a useful tool to understand many disease conditions including cardiovascular disease such as valvular heart disease(s) (VHD). VHD involves damage to heart valves, mostly presenting as stenosis, regurgitation or prolapse and can be classified into degenerative, rheumatic, congenital, or prosthetic valve disease. Gaps remain in our understanding of the pathogenesis of the common VHD. It is now fitting to place into perspective the contribution of metabolomics in the mechanism of development, diagnosis, and prognosis of VHD. A structured search for metabolomics studies centred on human VHD was undertaken. Biomarkers associated with the pathogenesis of bicuspid aortic valve disease, mitral valve disease, rheumatic heart disease, and degenerative aortic valve stenosis are reviewed and discussed. In addition, metabolic biomarkers reported to prognosticate patient outcomes of post-valve repair or replacement are highlighted. Finally, we also review the pitfalls and limitations to consider when designing metabolomics studies, especially from a clinician's viewpoint. In the future, reliable and simple metabolic biomarker(s) may supplement the existing diagnostic tools in the early diagnosis of VHD.
No takes yet. Share an insight, caveat, or question.
Mutithu et al. (2023) conducted a review in Valvular heart disease. Metabolomic profiling was evaluated. High-throughput metabolomics techniques show potential in identifying metabolic biomarkers for the pathogenesis, early diagnosis, and prognosis of common valvular heart diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: